Heron Therapeutics, Inc. (NASDAQ:HRTX) Receives Average Rating of “Hold” from Brokerages

Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) have been assigned a consensus recommendation of “Hold” from the five analysts that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have issued a buy recommendation on the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $4.50.

Several equities research analysts have weighed in on HRTX shares. Jefferies Financial Group reaffirmed a “buy” rating on shares of Heron Therapeutics in a research note on Tuesday, November 4th. Zacks Research raised Heron Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 7th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Heron Therapeutics in a research note on Wednesday, October 8th.

Heron Therapeutics Stock Performance

NASDAQ HRTX opened at $1.28 on Wednesday. The stock has a market capitalization of $234.70 million, a P/E ratio of -14.22 and a beta of 1.34. The business has a 50 day simple moving average of $1.21 and a 200 day simple moving average of $1.47. The company has a debt-to-equity ratio of 19.89, a current ratio of 2.56 and a quick ratio of 1.78. Heron Therapeutics has a one year low of $1.00 and a one year high of $2.68.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.03). The firm had revenue of $38.21 million for the quarter, compared to the consensus estimate of $39.03 million. Research analysts expect that Heron Therapeutics will post -0.13 earnings per share for the current year.

Institutional Trading of Heron Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. PKS Advisory Services LLC bought a new position in shares of Heron Therapeutics in the third quarter valued at $25,000. R Squared Ltd acquired a new stake in shares of Heron Therapeutics in the 2nd quarter worth about $26,000. B. Riley Wealth Advisors Inc. bought a new position in Heron Therapeutics in the 2nd quarter valued at about $26,000. Jones Financial Companies Lllp lifted its position in Heron Therapeutics by 5,541.2% in the 3rd quarter. Jones Financial Companies Lllp now owns 24,088 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 23,661 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV acquired a new position in Heron Therapeutics during the 3rd quarter valued at about $34,000. Institutional investors own 80.01% of the company’s stock.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.